CD69 and neoplasm: In most cases, T-cells (both CD4+ and CD8+) in the tumor microenvironment display an activated phenotype represented by an increased expression of activation markers (i.e., CD69, CD25, CD95, CD44, and HLA-DR) and concomitant decrease in naive T-cells markers (CD45RA and CCR7).